GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzon Pharmaceuticals Inc (OTCPK:ENZN) » Definitions » Insider Ownership

Enzon Pharmaceuticals (Enzon Pharmaceuticals) Insider Ownership : 5.52 % (As of Apr. 29, 2024)


View and export this data going back to 1984. Start your Free Trial

What is Enzon Pharmaceuticals Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Enzon Pharmaceuticals's insider ownership is 5.52%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Enzon Pharmaceuticals's Institutional Ownership is 0.02%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Enzon Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 40.71%.


Enzon Pharmaceuticals Insider Ownership Historical Data

The historical data trend for Enzon Pharmaceuticals's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzon Pharmaceuticals Insider Ownership Chart

Enzon Pharmaceuticals Historical Data

The historical data trend for Enzon Pharmaceuticals can be seen below:

2018-02-28 2018-03-31 2018-04-30 2018-05-31 2018-06-30 2018-07-31 2018-08-31 2018-09-30 2018-10-31 2018-11-30
Insider Ownership 5.52 5.52 5.52 5.52 5.52 5.52 5.52 5.52 5.52 5.52

Enzon Pharmaceuticals Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Enzon Pharmaceuticals (Enzon Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
20 Commerce Drive, Suite 135, Cranford, NJ, USA, 07016
Enzon Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology. The company earns revenue in the form of royalties. Primary source of royalty revenues derived from the sales of PegIntron, which is marketed by Merck.
Executives
Randolph C Read director C/O NEW YORK REIT, INC., 405 PARK AVENUE, NEW YORK NY 10022
Jaffrey Adam Firestone director C/O CVR ENERGY, INC., 2277 PLAZA DRIVE, SUITE 500, SUGAR LAND TX 77479
Family Fund Couchman other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jordan Bleznick director C/O ENZON PHANNACEUTICALS, INC., 120 COMMERCE DRIVE (SUITE 135), CRANFORD NJ 07016
Pearce Michael Cooper other: See explanation of responses 213 RHODODENDRON DRIVE, CHAPEL HILL NC 27517
Harper Asset Management Llc other: See explanation of responses 2945 S CENTER GREEN CT, G215, BOULDER CO 80301
Brian James Harper other: See explanation of responses 6680 GUNPARK DRIVE, SUITE 202B, BOULDER CO 80301
Myrexis, Inc. other: See Footnote 1 600 FIFTH AVENUE, 2ND FLOOR, NEW YORK NY 10020
Xstelos Corp. other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Jonathan Couchman 10 percent owner, other: See Footnote 1 630 FIFTH AVENUE, SUITE 2260, NEW YORK NY 10020
Carl C Icahn 10 percent owner C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH-1, SUNNY ISLES BEACH FL 33160
Richard L Feinstein officer: VP-Finance and PFO
Jonathan Christodoro director C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
Kostas D Odysseas director 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Jennifer Isacoff Mcnealey director C/O CODEX DNA, INC., 9535 WAPLES STREET, SUITE 100, SAN DIEGO Z4 92121